Expansion in the US continues into 2023
As we wrap up 2022, we take the opportunity to celebrate the clinics that have been part of and continue to support our expansion in… Read More »Expansion in the US continues into 2023
As we wrap up 2022, we take the opportunity to celebrate the clinics that have been part of and continue to support our expansion in… Read More »Expansion in the US continues into 2023
Attention deficit disorder (ADHD) has been shown to negatively impact cognition across many domains, including attention, inhibition, memory, and general functionality in daily life.1,2 Initially… Read More »Detecting & Managing Adult ADHD
The Meaning Behind Our New Name: Firefly Neuroscience Our new logo embraces the evocative, exciting nature of the firefly by tracing its path across the… Read More »The Meaning Behind Firefly Neuroscience
Normative Database Firefly Neuroscience’s proprietary commercial database is based on the normative dataset that is the bedrock of our new 510(K) cleared BNA™ Platform V1.0… Read More »Making the Complex Actionable: The Science and Process Behind the BNA™ Report
Recently, a leading pharmaceutical company used our BNA™ platform, powered by our age-matched, normative, comparative database to assess the effects of an SNRI antidepressant on… Read More »Identifying Neurological Biomarkers to Aid in Major Depressive Disorder Diagnosis and Treatment
Introduction Mild cognitive impairment (MCI) defines the intermediate state between healthy cognition and early dementia1 and is not typical for normal brain aging2. In 2020… Read More »Screening & Managing MCI
BNA could improve the treatment of depression significantly by objectively measuring brain health, improving and saving lives. The BNATM Product provides brain mapping imaging technology supporting clinicians in diagnosing cognitive disorders and monitoring and quantifying improvement.